{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:01:44Z","timestamp":1792929704508,"version":"4.5.0"},"reference-count":112,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1136\/jnnp-2016-313300","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T01:39:19Z","timestamp":1474940359000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":265,"title":["Neurodegeneration in multiple sclerosis and neuromyelitis optica"],"prefix":"10.1136","volume":"88","author":[{"given":"Izumi","family":"Kawachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"key-10.1136\/jnnp-2016-313300-1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"key-10.1136\/jnnp-2016-313300-2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(15)00313-0","article-title":"The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research","volume":"15","author":"Hohlfeld","year":"2016","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1474-4422(15)00334-8","article-title":"The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets","volume":"15","author":"Hohlfeld","year":"2015","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-5","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrn3275","article-title":"Will the real multiple sclerosis please stand up?","volume":"13","author":"Stys","year":"2012","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"key-10.1136\/jnnp-2016-313300-8","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2016-313300-11","first-page":"17","article-title":"Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: results of the IFN-beta-1a-controlled, double-blind, Phase III OPERA I and II studies","volume":"22","author":"Hauser","year":"2016","journal-title":"Mult Scler J"},{"key":"key-10.1136\/jnnp-2016-313300-12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/1352458514523496","article-title":"Differential effects of fingolimod on B-cell populations in multiple sclerosis","volume":"20","author":"Nakamura","year":"2014","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313300-15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaci.2014.01.037","article-title":"Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis","volume":"134","author":"Sic","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.1136\/jnnp-2016-313300-16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-17","article-title":"Natalizumab Versus Placebo in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Results from ASCEND, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 3 Clinical Trial","author":"Steiner"},{"key":"key-10.1136\/jnnp-2016-313300-18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2016-313300-19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1352458514561911","article-title":"The Charcot Lecture | beating MS: a story of B cells, with twists and turns","volume":"21","author":"Hauser","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313300-21","first-page":"781","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis\u2014results of the placebo-controlled, double-blind, phase III ORATORIO study","volume":"23","author":"Montalban","year":"2015","journal-title":"Mult Scler J"},{"key":"key-10.1136\/jnnp-2016-313300-22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.24632","article-title":"Demyelination and neurodegeneration in multiple sclerosis: the role of hypoxia","volume":"79","author":"Lassmann","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-25","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1093\/brain\/awm236","article-title":"Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?","volume":"130","author":"Marik","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-26","first-page":"554","article-title":"Histologie de la scl\u00e9rose en plaques","volume":"140","author":"Charcot","year":"1868","journal-title":"Gaz Hop Civils et Militaires"},{"key":"key-10.1136\/jnnp-2016-313300-27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1750-3639.1999.tb00547.x","article-title":"Axonal pathology in multiple sclerosis. A historical note","volume":"9","author":"Kornek","year":"1999","journal-title":"Brain Pathol"},{"key":"key-10.1136\/jnnp-2016-313300-28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-29","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archneurol.2009.174","article-title":"Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis","volume":"66","author":"Calabrese","year":"2009","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/WNL.0000000000001285","article-title":"Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis","volume":"84","author":"Schoonheim","year":"2015","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-32","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamaneurol.2015.1241","article-title":"Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis","volume":"72","author":"Harrison","year":"2015","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1212\/WNL.0b013e3182a08ce8","article-title":"Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS","volume":"81","author":"Nielsen","year":"2013","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2008.11.018","article-title":"Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS","volume":"282","author":"Rudick","year":"2009","journal-title":"J Neurol Sci"},{"key":"key-10.1136\/jnnp-2016-313300-35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1148\/radiol.10100326","article-title":"Thalamic damage and long-term progression of disability in multiple sclerosis","volume":"257","author":"Rocca","year":"2010","journal-title":"Radiology"},{"key":"key-10.1136\/jnnp-2016-313300-36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jnen\/62.7.723","article-title":"Subpial demyelination in the cerebral cortex of multiple sclerosis patients","volume":"62","author":"Bo","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1474-4422(08)70191-1","article-title":"Grey matter pathology in multiple sclerosis","volume":"7","author":"Geurts","year":"2008","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/nyas.12841","article-title":"Pathological differences between white and grey matter multiple sclerosis lesions","volume":"1351","author":"Prins","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.1136\/jnnp-2016-313300-39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/neup.12216","article-title":"Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica","volume":"35","author":"Kawachi","year":"2015","journal-title":"Neuropathology"},{"issue":"11","key":"key-10.1136\/jnnp-2016-313300-40","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00401-015-1500-6","article-title":"Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants","volume":"130","author":"Blauth","year":"2015","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2016-313300-42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e31824528a0","article-title":"Postmortem verification of MS cortical lesion detection with 3D DIR","volume":"78","author":"Seewann","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-43","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","article-title":"Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron","volume":"85","author":"Haider","year":"2014","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313300-44","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1212\/NXI.0000000000000102","article-title":"Early CNS neurodegeneration in radiologically isolated syndrome","volume":"2","author":"Azevedo","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2016-313300-45","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/jnnp.2007.134825","article-title":"Regional grey matter atrophy in clinically isolated syndromes at presentation","volume":"79","author":"Henry","year":"2008","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313300-46","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000069464.22267.95","article-title":"Thalamic neurodegeneration in relapsing-remitting multiple sclerosis","volume":"60","author":"Wylezinska","year":"2003","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ana.22337","article-title":"Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients","volume":"69","author":"Dutta","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1750-3639.2006.00041.x","article-title":"Widespread demyelination in the cerebellar cortex in multiple sclerosis","volume":"17","author":"Kutzelnigg","year":"2007","journal-title":"Brain Pathol"},{"key":"key-10.1136\/jnnp-2016-313300-49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ana.21799","article-title":"Substantial early, but nonprogressive neuronal loss in multiple sclerosis (MS) spinal cord","volume":"66","author":"Schirmer","year":"2009","journal-title":"Ann Neurol"},{"issue":"10","key":"key-10.1136\/jnnp-2016-313300-50","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/brain\/awf235","article-title":"Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time","volume":"125","author":"Kuhlmann","year":"2002","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1750-3639.2010.00466.x","article-title":"Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis","volume":"21","author":"Schirmer","year":"2011","journal-title":"Brain Pathol"},{"key":"key-10.1136\/jnnp-2016-313300-52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrneurol.2009.41","article-title":"Imaging outcomes for neuroprotection and repair in multiple sclerosis trials","volume":"5","author":"Barkhof","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann Neurol"},{"issue":"3","key":"key-10.1136\/jnnp-2016-313300-56","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/awv398","article-title":"The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain","volume":"139","author":"Haider","year":"2016","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3681","article-title":"Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation","volume":"20","author":"Mayo","year":"2014","journal-title":"Nat Med"},{"issue":"3","key":"key-10.1136\/jnnp-2016-313300-58","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","article-title":"NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury","volume":"135","author":"Fischer","year":"2012","journal-title":"Brain"},{"issue":"6","key":"key-10.1136\/jnnp-2016-313300-59","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/brain\/awt110","article-title":"Disease-specific molecular events in cortical multiple sclerosis lesions","volume":"136","author":"Fischer","year":"2013","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-60","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1056\/NEJMra1215233","article-title":"Mitochondrial dynamics\u2014mitochondrial fission and fusion in human diseases","volume":"369","author":"Archer","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313300-61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","article-title":"A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"17","author":"Nikic","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"key-10.1136\/jnnp-2016-313300-62","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/brain\/awr110","article-title":"Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis","volume":"134","author":"Zambonin","year":"2011","journal-title":"Brain"},{"issue":"5","key":"key-10.1136\/jnnp-2016-313300-63","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","article-title":"Mitochondrial changes within axons in multiple sclerosis","volume":"132","author":"Mahad","year":"2009","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.22109","article-title":"Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis","volume":"69","author":"Campbell","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molmed.2013.11.007","article-title":"Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis","volume":"20","author":"Witte","year":"2014","journal-title":"Trends Mol Med"},{"key":"key-10.1136\/jnnp-2016-313300-66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-67","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-68","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24607","article-title":"Cause and prevention of demyelination in a model multiple sclerosis lesion","volume":"79","author":"Desai","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-69","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm1210-1370","article-title":"Neurodegeneration and the neurovascular unit","volume":"16","author":"Zlokovic","year":"2010","journal-title":"Nat Med"},{"key":"key-10.1136\/jnnp-2016-313300-70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrn3680","article-title":"Wallerian degeneration: an emerging axon death pathway linking injury and disease","volume":"15","author":"Conforti","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"key-10.1136\/jnnp-2016-313300-71","doi-asserted-by":"crossref","first-page":"9794","DOI":"10.1523\/JNEUROSCI.2116-06.2006","article-title":"Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models","volume":"26","author":"Kaneko","year":"2006","journal-title":"J Neurosci"},{"key":"key-10.1136\/jnnp-2016-313300-72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1750-3639.2010.00401.x","article-title":"Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis","volume":"20","author":"Dziedzic","year":"2010","journal-title":"Brain Pathol"},{"key":"key-10.1136\/jnnp-2016-313300-73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"key-10.1136\/jnnp-2016-313300-74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/brain\/awt314","article-title":"Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody","volume":"137","author":"Yokoseki","year":"2014","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-75","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.53.8.1628","article-title":"Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors","volume":"53","author":"De Keyser","year":"1999","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/jcbfm.2011.193","article-title":"White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis","volume":"32","author":"Cambron","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"key-10.1136\/jnnp-2016-313300-77","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-79","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ana.24608","article-title":"Clinicopathological features in anterior visual pathway in neuromyelitis optica","volume":"79","author":"Hokari","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313300-81","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-82","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-83","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis xoptica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-85","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamaneurol.2015.0248","article-title":"Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder","volume":"72","author":"Kremer","year":"2015","journal-title":"JAMA Neurol"},{"issue":"5","key":"key-10.1136\/jnnp-2016-313300-86","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"issue":"5","key":"key-10.1136\/jnnp-2016-313300-87","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"issue":"7","key":"key-10.1136\/jnnp-2016-313300-88","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313300-89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/2051-5960-1-85","article-title":"T cell-activation in neuromyelitis optica lesions plays a role in their formation","volume":"1","author":"Pohl","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"key-10.1136\/jnnp-2016-313300-90","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.0b013e3181c1deb9","article-title":"Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis","volume":"73","author":"Yanagawa","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-91","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-92","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"key-10.1136\/jnnp-2016-313300-93","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2016-313300-94","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","article-title":"Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica","volume":"286","author":"Ratelade","year":"2011","journal-title":"J Biol Chem"},{"key":"key-10.1136\/jnnp-2016-313300-95","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","article-title":"Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica","volume":"125","author":"Misu","year":"2013","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2016-313300-96","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24630","article-title":"In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology","volume":"79","author":"Herwerth","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-97","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1212\/WNL.0b013e318200d80c","article-title":"Absence of cortical demyelination in neuromyelitis optica","volume":"75","author":"Popescu","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-98","first-page":"398259","article-title":"Ultrahigh-field MR (7T) imaging of brain lesions in neuromyelitis optica","volume":"2013","author":"Kister","year":"2013","journal-title":"Mult Scler Int"},{"key":"key-10.1136\/jnnp-2016-313300-99","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","article-title":"Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis","volume":"79","author":"Sinnecker","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-100","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1212\/WNL.0b013e31826e9a96","article-title":"No MRI evidence of cortical lesions in neuromyelitis optica","volume":"79","author":"Calabrese","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-101","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1212\/NXI.0000000000000229","article-title":"Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD","volume":"3","author":"Finke","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2016-313300-102","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"key":"key-10.1136\/jnnp-2016-313300-103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.expneurol.2014.12.015","article-title":"The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model","volume":"265","author":"Geis","year":"2015","journal-title":"Exp Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313300-106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-107","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2377-14-21","article-title":"Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension","volume":"14","author":"Kira","year":"2014","journal-title":"BMC Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.22054","article-title":"Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords","volume":"68","author":"Androdias","year":"2010","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-109","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","article-title":"Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination","volume":"124","author":"Bruck","year":"2012","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2016-313300-110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/glia.22443","article-title":"The astrocyte in multiple sclerosis revisited","volume":"61","author":"Brosnan","year":"2013","journal-title":"Glia"},{"key":"key-10.1136\/jnnp-2016-313300-111","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ana.23974","article-title":"Iron and neurodegeneration in the multiple sclerosis brain","volume":"74","author":"Hametner","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313300-112","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/nm.3015","article-title":"TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"18","author":"Schattling","year":"2012","journal-title":"Nat Med"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2016-313300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:11:42Z","timestamp":1718813502000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2016-313300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/jnnp-2016-313300"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2016-313300","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}